Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Penumbra, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results

      Penumbra, Inc. Logo (PRNewsFoto/Penumbra, Inc.)

      News provided by

      Penumbra, Inc.

      Feb 18, 2025, 16:05 ET

      Share this article

      Share this article


      ALAMEDA, Calif., Feb. 18, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the fourth quarter and full year ended December 31, 2024.

      Financial Highlights:

      • Adjusted revenue1 of $321.3 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2 compared to the fourth quarter of 2023.
      • Adjusted revenue1 of $1,200.4 million, excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, an increase of 13.4% in adjusted2 and adjusted constant currency2 compared to the full year 2023.
      • Revenue of $315.5 million for the fourth quarter of 2024, an increase of 10.8% in reported and constant currency2 compared to the fourth quarter of 2023.
      • Revenue of $1,194.6 million for the full year 2024, an increase of 12.9% or 12.8% in constant currency2 compared to the full year 2023.
      • Income from operations of $42.8 million and Non-GAAP income from operations2 of $48.6 million in the fourth quarter of 2024.
      • Income from operations of $9.3 million and Non-GAAP income from operations2 of $106.6 million for the full year 2024.
      • Net income of $33.7 million and adjusted EBITDA2 of $63.7 million or net income margin of 10.7% and adjusted EBITDA margin2 of 19.8% in the fourth quarter of 2024.
      • Net income of $14.0 million and adjusted EBITDA2 of $171.0 million or net income margin of 1.2% and adjusted EBITDA margin2 of 14.2% for the full year 2024.

      Fourth Quarter 2024 Financial Results
      Adjusted total revenue1 increased to $321.3 million for the fourth quarter of 2024 compared to $284.7 million for the fourth quarter of 2023, an increase of 12.9% adjusted2 or 13.0% in adjusted constant currency2. The United States represented 77.2% of adjusted total revenue1 and international represented 22.8% of adjusted total revenue1 for the fourth quarter of 2024. Adjusted total revenue1 from the U.S. increased 21.7% while revenue from our international regions decreased 9.4% adjusted2, or 9.1% in adjusted constant currency2. Adjusted total revenue1 from sales of our global thrombectomy products grew to $222.7 million in the fourth quarter of 2024, an increase of 16.8% adjusted2, or 16.9% in adjusted constant currency2 over the same period a year ago, driven primarily by the sales our U.S. thrombectomy products which increased by 27.3% which was partially offset by a 13.9% decline in adjusted revenue1 from international regions due to a decline in China revenue offset in part by increases in all other international regions. Adjusted total revenue1 from sales of our global embolization and access products grew to $98.6 million in the fourth quarter of 2024, an increase of 5.0% adjusted2, or 5.1% in adjusted constant currency2 over the same period a year ago, driven primarily by our U.S embolization and access products.

      Total revenue increased to $315.5 million for the fourth quarter of 2024 compared to $284.7 million for the fourth quarter of 2023, an increase of 10.8% in reported and constant currency2. The United States represented 78.6% of total revenue and international represented 21.4% of total revenue for the fourth quarter of 2024. Revenue from the U.S. increased 21.7% while revenue from our international regions decreased 16.5%, or 16.6% in constant currency2. Revenue from sales of our global thrombectomy products grew to $220.1 million in the fourth quarter of 2024, an increase of 15.4% in reported and constant currency2 over the same period a year ago, driven primarily by the sales of our U.S. thrombectomy products which increased by 27.3%. Revenue from sales of our global embolization and access products grew to $95.4 million in the fourth quarter of 2024, an increase of 1.6%, or 1.5% in constant currency2 from the same period a year ago, driven primarily by our U.S. embolization and access products which increased by 8.9% from the same period a year ago.

      Gross profit, including the $5.8 million impact of the Italian government's payback provision pertaining to prior years, for the fourth quarter of 2024 was $210.7 million, or 66.8% of total revenue. Excluding the impact of the Italian government's payback provision, adjusted gross profit2 was $216.5 million, or 67.4% of adjusted total revenue1 for the fourth quarter of 2024 compared to GAAP and adjusted gross profit2 of $187.0 million, or 65.7% of total revenue for the fourth quarter of 2023. Gross margin is impacted by product mix, regional mix, and production initiatives to support demand and create future efficiencies. As such, with favorable product mix, improvement in productivity, and by leveraging our fixed costs on higher volume of new product sales during the year, our gross margin may be positively impacted in the future.

      Total operating expenses and total non-GAAP operating expenses2 were $167.9 million, or 53.2% of total revenue and 52.3% of adjusted revenue1 for the fourth quarter of 2024. This compares to total operating expenses of $152.0 million, or 53.4% of total revenue for the fourth quarter of 2023, which included a $2.4 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition. Excluding the charge noted above, total non-GAAP operating expenses2 were $149.6 million, or 52.5% of total revenue for the fourth quarter of 2023. R&D expenses were $20.0 million for the fourth quarter of 2024, compared to $21.9 million for the fourth quarter of 2023. SG&A expenses were $147.9 million for the fourth quarter of 2024, compared to $130.0 million for the fourth quarter of 2023.

      Income from operations was $42.8 million for the fourth quarter of 2024 compared to income from operations of $35.0 million for the fourth quarter of 2023. Excluding the $5.8 million impact of the Italian government's payback provision pertaining to prior years, non-GAAP income from operations2 was $48.6 million for the fourth quarter of 2024. This compares to non-GAAP income from operations2 of $37.4 million for the fourth quarter of 2023, which excludes the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition.

      Full Year 2024 Financial Results
      Adjusted total revenue1 increased to $1,200.4 million for the year ended December 31, 2024, an increase of 13.4% in adjusted2 and adjusted constant currency2 compared to $1,058.5 million for the year ended December 31, 2023.

      Total revenue increased to $1,194.6 million for the year ended December 31, 2024 compared to $1,058.5 million for the year ended December 31, 2023, an increase of 12.9%, or 12.8% in constant currency2. The United States represented 75.5% of total revenue and international represented 24.5% of total revenue for the year ended December 31, 2024. Revenue from the U.S. increased 19.1% while revenue from our international regions decreased 2.9%, or 3.1% in constant currency2. Revenue from sales of our global thrombectomy products grew to $815.5 million for the year ended December 31, 2024, an increase of 20.4% in reported and constant currency2 over the same period a year ago, driven primarily by the sales of our U.S. thrombectomy products which increased by 26.8%. Revenue from sales of our global embolization and access products declined to $379.1 million for the year ended December 31, 2024, a decrease of 0.5%, or 0.7% in constant currency2 from the same period a year ago, driven primarily by our international embolization and access products which decreased by 7.6%, or 7.9% in constant currency2, partially offset by a 3.3% increase in sales of our U.S. embolization and access products.

      Gross profit, including the $5.8 million impact of the Italian government's payback provision pertaining to prior years and a one-time $33.4 million inventory impairment charge to cost of revenue in connection with the impairment of our Immersive Healthcare asset group, for the year ended December 31, 2024 was $755.0 million, or 63.2% of total revenue, compared to $682.6 million, or 64.5% of total revenue, for the year ended December 31, 2023. The impact of the $5.8 million Italian payback provision and one-time $33.4 million charge decreased our gross margin by 3.0 percentage points in 2024. Gross margin is impacted by product mix, regional mix, and production initiatives to support demand and create future efficiencies. As such, with favorable product mix, improvement in productivity, and by leveraging our fixed costs on higher volume of new product sales during the year, our gross margin may be positively impacted in the future.

      Total operating expenses for the year ended December 31, 2024 were $745.7 million, or 62.4% of total revenue, which included $5.0 million of one-time expenses in connection with the wind down of the Immersive Healthcare business, a $76.9 million long-lived asset impairment charge associated with the impairment of assets related to our Immersive Healthcare business, $4.8 million in non-recurring litigation related expenses, and a $4.8 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition. This compares to total operating expenses of $609.1 million, or 57.5% of total revenue, for the year ended December 31, 2023, which included a one-time $18.2 million expense associated with the acquisition of in-process research and development ("IPR&D") and a $9.5 million amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition. Excluding the charges noted above, total non-GAAP operating expenses2 were $654.2 million, or 54.8% of total revenue during the year ended December 31, 2024, and $581.4 million, or 54.9% of total revenue during the year ended December 31, 2023. R&D expenses were $94.8 million for the year ended December 31, 2024, compared to $84.4 million for the year ended December 31, 2023. SG&A expenses were $574.0 million for the year ended December 31, 2024, compared to $506.5 million for the year ended December 31, 2023.

      Income from operations was $9.3 million for the year ended December 31, 2024 compared to income from operations of $73.6 million for the year ended December 31, 2023. Excluding impact of the Italian government's payback provision of $5.8 million, one-time expenses in connection with the wind down of the Immersive Healthcare business of $5.0 million, a $76.9 million long-lived asset impairment charge associated with the impairment of assets related to our Immersive Healthcare business, $4.8 million in non-recurring litigation related expenses, and amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition of $4.8 million, non-GAAP income from operations2 was $106.6 million for the year ended December 31, 2024. This compares to non-GAAP income from operations2 of $101.3 million for the year ended December 31, 2023, excluding the one-time expense associated with the acquired IPR&D of $18.2 million and the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition of $9.5 million.

      1Adjusted revenue excludes $5.8 million due to the Italian government's payback provision.

      2See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

      Full Year 2025 Financial Outlook
      The Company projects total revenue for 2025 to be in the range of $1,340.0 million to $1,360.0 million, representing year over year growth of 12% to 14% compared to 2024 revenue of $1,194.6 million. The Company projects the U.S. thrombectomy franchise will grow 19% to 20% year-over-year, driven primarily by its computer assisted vacuum thrombectomy (CAVT) products. The Company expects gross margin expansion of at least 100 basis points in 2025, to more than 67% for the full year, and operating margin expansion to a range of 13% to 14% of revenue for full year 2025.

      Webcast and Conference Call Information
      Penumbra, Inc. will host a conference call to discuss financial results for the fourth quarter and year ended December 31, 2024 after market close on Tuesday, February 18, 2025 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 5872954), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at: www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.

      About Penumbra
      Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.

      Non-GAAP Financial Measures
      In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures in this press release: a) constant currency and adjusted constant currency, b) adjusted revenue, adjusted gross profit, adjusted gross margin, non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income and non-GAAP diluted earnings per share ("EPS") and c) adjusted EBITDA.

      Constant currency and adjusted constant currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business. The Company's adjusted constant currency revenue disclosures are calculated in the same manner as above but uses adjusted revenue, described below, and accordingly excludes the impact of the Italian government's payback provision pertaining to prior years.

      Adjusted Revenue. The adjustments to the GAAP financial measure reflect the exclusion of impact of the Italian government's payback provision pertaining to prior years. During the year ended December 31, 2024, the Company recorded a reduction in revenue of $7.3 million related to the Italian payback provision pertaining to the years 2015 through 2024, of which $5.8 million pertained to prior years.

      Adjusted gross profit and adjusted gross margin. The adjustments to the GAAP financial measures reflect the exclusion of impact of the Italian government's payback provision pertaining to prior years.

      Non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:

      • the one-time expense associated with the acquisition of IPR&D in the third quarter of 2023;
      • the effect of the amortization of finite lived intangible assets acquired in connection with the Sixense acquisition over their estimated useful lives;
      • the excess tax benefits associated with share-based compensation arrangements;
      • the release of the valuation allowance associated with Federal R&D tax credits and partial release of the valuation allowance associated with California deferred tax assets;
      • non-recurring litigation related expenses;
      • non-cash long-lived asset impairment related to the impairment of our Immersive Healthcare asset group;
      • one-time expenses in connection with the wind down of the Immersive Healthcare business; and
      • the Italian government's payback provision pertaining to prior years.

      Adjusted EBITDA. The Company's adjusted EBITDA reflects the exclusion from GAAP net income of:

      • non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges;
      • non-operating items such as the one-time expense associated with the acquisition of IPR&D, interest income, interest expense, and provision for (benefit from) income taxes;
      • non-recurring litigation related expenses;
      • one-time expenses in connection with the wind down of the Immersive Healthcare business; and
      • the Italian government's payback provision pertaining to prior years.

      Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.

      Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider adjusted revenue, adjusted gross profit and adjusted gross margin useful metrics to investors as they eliminate the impact of the Italian government's payback provision pertaining to prior years and allow a more direct comparison of our business performance between periods. We consider non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding the one-time expense associated with the acquisition of IPR&D in the third quarter of 2023, the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, the excess tax benefits associated with share-based compensation arrangements, the release of the valuation allowance associated with Federal R&D tax credits and partial release of the valuation allowance associated with California deferred tax assets, expenses related to certain litigation matters that we have determined are not a normal or recurring part of our business, including settlement costs and legal fees, non-cash long-lived asset impairment related to the impairment of our Immersive Healthcare asset group, one-time expenses in connection with the wind down of the Immersive Healthcare business, and the Italian government's payback provision pertaining to prior years. Further, we consider adjusted EBITDA a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the Italian government's payback provision pertaining to prior years, non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges, non-operating items such as the one-time expense associated with the acquisition of IPR&D, interest income, interest expense, and provision for (benefit from) income taxes, non-recurring litigation related expenses, and one-time expenses in connection with the wind down of the Immersive Healthcare business.

      The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.

      Forward-Looking Statements
      Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024, which we expect to file with the SEC on or before March 3, 2025. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.

      Penumbra, Inc.

      Condensed Consolidated Balance Sheets

      (unaudited)

      (in thousands)




      December 31,



      2024


      2023

      Assets





      Current assets:





           Cash and cash equivalents


      $           324,404


      $           167,486

           Marketable investments


      15,727


      121,701

           Accounts receivable, net


      167,668


      201,768

           Inventories


      406,737


      388,023

           Prepaid expenses and other current assets


      36,589


      36,424

                Total current assets


      951,125


      915,402

      Property and equipment, net


      62,641


      72,691

      Operating lease right-of-use assets


      177,787


      188,756

      Finance lease right-of-use assets


      28,018


      31,092

      Intangible assets, net


      6,513


      71,056

      Goodwill


      165,826


      166,270

      Deferred taxes


      100,332


      85,158

      Other non-current assets


      40,939


      25,880

                Total assets


      $        1,533,181


      $        1,556,305

      Liabilities and Stockholders' Equity





      Current liabilities:





           Accounts payable


      $             31,326


      $             27,155

           Accrued liabilities


      112,429


      110,555

           Current operating lease liabilities


      12,221


      11,203

           Current finance lease liabilities


      2,369


      2,231

                Total current liabilities


      158,345


      151,144

      Non-current operating lease liabilities


      187,068


      197,229

      Non-current finance lease liabilities


      21,731


      23,680

      Other non-current liabilities


      15,106


      5,308

                Total liabilities


      382,250


      377,361

      Stockholders' equity:





      Preferred stock


      —


      —

      Common stock


      38


      39

      Additional paid-in capital


      1,096,732


      1,047,198

      Accumulated other comprehensive loss


      (5,843)


      (3,151)

      Retained earnings


      60,004


      134,858

      Total stockholders' equity


      1,150,931


      1,178,944

      Total liabilities and stockholders' equity


      $        1,533,181


      $        1,556,305

      Penumbra, Inc.

      Condensed Consolidated Statements of Operations

      (unaudited)

      (in thousands, except share and per share amounts)




      Three Months Ended December 31,


      Year Ended December 31,



      2024


      2023


      2024


      2023

      Revenue


      $            315,518


      $            284,679


      $         1,194,615


      $         1,058,522

      Cost of revenue


      104,797


      97,687


      439,620


      375,879

           Gross profit


      210,721


      186,992


      754,995


      682,643

      Operating expenses:









           Research and development


      20,010


      21,942


      94,783


      84,423

           Sales, general and administrative


      147,936


      130,021


      573,988


      506,454

           Acquired in-process research and development


      —


      —


      —


      18,215

           Impairment Charge


      —


      —


      76,945


      —

                Total operating expenses


      167,946


      151,963


      745,716


      609,092

      Income from operations


      42,775


      35,029


      9,279


      73,551

      Interest and other income (expense), net


      1,564


      3,129


      11,590


      6,099

      Income before income taxes


      44,339


      38,158


      20,869


      79,650

      Provision for (benefit from) income taxes


      10,656


      (16,060)


      6,857


      (11,304)

      Net income


      $              33,683


      $              54,218


      $              14,012


      $              90,954










      Net income per share:









      Basic


      $                  0.88


      $                  1.40


      $                  0.36


      $                  2.37

      Diluted


      $                  0.86


      $                  1.38


      $                  0.36


      $                  2.32

      Weighted average shares outstanding:









      Basic


      38,418,269


      38,628,565


      38,633,744


      38,401,171

      Diluted


      39,037,644


      39,291,044


      39,268,037


      39,216,564

      Penumbra, Inc.

      Reconciliation of GAAP Revenue, GAAP Gross Profit and GAAP Gross Margin to Adjusted Revenue, Non-GAAP Gross Profit
      and Non-GAAP Gross Margin1

      (unaudited)

      (in thousands, except for percentages)




      Three Months Ended December 31,


      Year Ended December 31,



      2024


      2023


      2024


      2023

      GAAP revenue


      $           315,518


      $           284,679


      $     1,194,615


      $     1,058,522

      Italian payback measure2


      5,797


      —


      5,797


      —

      Adjusted revenue2


      321,315


      284,679


      1,200,412


      1,058,522










      GAAP gross profit


      210,721


      186,992


      754,995


      682,643

      GAAP gross profit includes the effect of the following item:









      Italian payback measure2


      5,797


      —


      5,797


      —

      Adjusted gross profit


      $           216,518


      $           186,992


      $        760,792


      $        682,643

      GAAP gross margin


      66.8 %


      65.7 %


      63.2 %


      64.5 %

      Adjusted gross margin


      67.4 %


      65.7 %


      63.4 %


      64.5 %






      1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

      2Represents the impact of the Italian government's payback provision pertaining to prior years during the three months ended December 31, 2024.

      Penumbra, Inc.

      Reconciliation of GAAP Operating Expenses and GAAP Income from Operations to Non-GAAP Operating Expenses and
      Non-GAAP Income from Operations1

      (unaudited)

      (in thousands)




      Three Months Ended December 31,


      Year Ended December 31,



      2024


      2023


      2024


      2023










      GAAP operating expenses


      $             167,946


      $             151,963


      $             745,716


      $             609,092

      GAAP operating expenses includes the effect of the following
      items:









      Impairment charge2


      —


      —


      76,945


      —

      Wind down expenses3


      —


      —


      4,971


      —

      Non-recurring litigation related expenses


      —


      —


      4,823


      —

      Amortization of finite lived intangible assets acquired


      —


      2,380


      4,759


      9,519

      Acquired IPR&D5


      —


      —


      —


      18,215

      Non-GAAP operating expenses


      $             167,946


      $             149,583


      $             654,218


      $             581,358










      GAAP income from operations


      $               42,775


      $               35,029


      $                 9,279


      $               73,551

      GAAP income from operations includes the effect of the
      following items:









      Impairment charge2


      —


      —


      76,945


      —

      Wind down expenses3


      —


      —


      4,971


      —

      Italian payback measures4


      5,797


      —


      5,797


      —

      Non-recurring litigation related expenses


      —


      —


      4,823


      —

      Amortization of finite lived intangible assets acquired


      —


      2,380


      4,759


      9,519

      Acquired IPR&D5


      —


      —


      —


      18,215

      Non-GAAP income from operations


      $               48,572


      $               37,409


      $             106,574


      $             101,285






      1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

      2Represents charges associated with the impairment of the Immersive Healthcare asset group during the three months ended June 30, 2024.

      3Represents one-time expenses that include severance and other costs related to the wind down of the Immersive Healthcare business during the three months ended September 30, 2024.

      4Represents the impact of the Italian government's payback provision pertaining to prior years during the three months ended December 31, 2024.

      5Represents a one-time $18.2 million expense associated with the acquisition of IPR&D during the three months ended September 30, 2023.

      Penumbra, Inc.

      Reconciliation of GAAP Net Income and GAAP Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS1

      (unaudited)

      (in thousands, except per share amounts)




      Three Months Ended

      December 31, 2024


      Three Months Ended

      December 31, 2023


      Year Ended

      December 31, 2024


      Year Ended

      December 31, 2023



      Net
      income


      Diluted
      EPS


      Net
      income


      Diluted
      EPS


      Net
      income


      Diluted
      EPS


      Net
      income


      Diluted
      EPS

      GAAP net income


      $    33,683


      $       0.86


      $    54,218


      $       1.38


      $    14,012


      $       0.36


      $    90,954


      $       2.32

      GAAP net income includes the effect of the
      following items:

















        Italian payback measure2


      5,797


      0.15


      —


      —


      5,797


      0.15


      —


      —

        Impairment charge3


      —


      —


      —


      —


      76,945


      1.96


      —


      —

        Wind down expenses4


      —


      —


      —


      —


      4,971


      0.13


      —


      —

        Non-recurring litigation expenses


      —


      —


      —


      —


      4,823


      0.12


      —


      —

        Amortization of finite lived intangible assets acquired


      —


      —


      2,380


      0.06


      4,759


      0.12


      9,519


      0.25

        Acquired IPR&D5


      —


      —


      —


      —


      —


      —


      18,215


      0.46

        Tax effect on the non-GAAP adjustments above6


      (1,217)


      (0.03)


      (573)


      (0.01)


      (23,387)


      (0.60)


      (2,293)


      (0.06)

        Excess tax benefits related to stock compensation
        awards


      (343)


      (0.01)


      (648)


      (0.02)


      (837)


      (0.02)


      (9,020)


      (0.23)

        Valuation allowance release7


      —


      —


      (25,493)


      (0.65)


      —


      —


      (25,493)


      (0.65)

      Non-GAAP net income


      $    37,920


      $       0.97


      $    29,884


      $       0.76


      $    87,083


      $       2.22


      $    81,882


      $       2.09


















      GAAP diluted EPS




      $       0.86




      $       1.38




      $       0.36




      $       2.32

      Non-GAAP diluted EPS




      $       0.97




      $       0.76




      $       2.22




      $       2.09






      1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

      2Represents the impact of the Italian government's payback provision pertaining to prior years during the three months ended December 31, 2024.

      3Represents charges associated with the impairment of the Immersive Healthcare asset group during the three months ended June 30, 2024.

      4Represents one-time expenses that include severance and other costs related to the wind down of the Immersive Healthcare business during the three months ended September 30, 2024.

      5Represents a one-time $18.2 million expense associated with the acquisition of IPR&D during the three months ended September 30, 2023.

      6For the three and twelve months ended December 31, 2024, management used a combined federal and state tax rate of 24.23% to compute the tax effect of non-GAAP measures, except for the Italian payback measure, which used a federal tax rate of 21.0%. For the three and twelve months ended December 31, 2023, management used a combined federal and state tax rate of 24.09% to compute the tax effect of non-GAAP measures.

      7The Company released a valuation allowance against its Federal R&D tax credits and partially released a valuation allowance against its California deferred tax assets, resulting in a tax benefit of $25.5 million during the three and twelve months ended December 31, 2023.

      Penumbra, Inc.

      Reconciliation of GAAP Net Income and GAAP Net Income Margin to Adjusted EBITDA and Adjusted EBITDA Margin1

      (unaudited)

      (in thousands, except for percentages)




      Three Months Ended December 31,


      Year Ended December 31,



      2024


      2023


      2024


      2023

      GAAP net income


      $          33,683


      $          54,218


      $          14,012


      $          90,954

      Adjustments to GAAP net income:









      Italian payback measure2


      5,797


      —


      5,797


      —

      Depreciation and amortization expense


      4,388


      7,039


      23,702


      27,257

      Interest income, net


      (2,939)


      (2,570)


      (12,272)


      (5,086)

      Provision for (benefit from) income taxes


      10,656


      (16,060)


      6,857


      (11,304)

      Stock-based compensation expense


      12,095


      10,791


      46,164


      50,516

      Impairment charge3


      —


      —


      76,945


      —

      Wind down expenses4


      —


      —


      4,971


      —

      Non-recurring litigation related expenses


      —


      —


      4,823


      —

      Acquired IPR&D5


      —


      —


      —


      18,215

      Adjusted EBITDA


      $          63,680


      $          53,418


      $        170,999


      $        170,552










      GAAP revenue


      $        315,518


      $        284,679


      $     1,194,615


      $     1,058,522

      Adjusted revenue2


      $        321,315


      284,679


      $     1,200,412


      $     1,058,522

      Adjusted EBITDA


      $          63,680


      $          53,418


      $        170,999


      $        170,552

      GAAP net income margin


      10.7 %


      19.0 %


      1.2 %


      8.6 %

      Adjusted EBITDA margin


      19.8 %


      18.8 %


      14.2 %


      16.1 %






      1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. 

      2Represents the impact of the Italian government's payback provision pertaining to prior years during the three months ended December 31, 2024.

      3Represents charges associated with the impairment of the Immersive Healthcare asset group during the three months ended June 30, 2024.

      4Represents one-time expenses that include severance and other costs related to the wind down of the Immersive Healthcare business during the three months ended September 30, 2024.

      5Represents a one-time $18.2 million expense associated with the acquisition of IPR&D during the three months ended September 30, 2023.

      Penumbra, Inc.

      Reconciliation of Revenue and Adjusted Revenue Change by Geographic Regions to Adjusted Constant Currency and
      Constant Currency Revenue Growth1

      (unaudited)

      (in thousands, except for percentages)




      Three Months Ended December 31,


      Reported
      Revenue
      Change
      (%)


      Adjusted
      Revenue
      Impact

      (%)


      Adjusted
      FX

      Impact
      (%)


      Adjusted
      Constant
      Currency
      (%)



      2024


      2023







      Adjusted
      Revenue


      Adjustment


      Revenue


      Adjusted
      revenue


      Adjustment


      Revenue





      United States


      $  247,917


      $           —


      $  247,917


      $  203,684


      $           —


      $  203,684


      21.7 %


      — %


      — %


      21.7 %

      International


      73,398


      (5,797)


      67,601


      80,995


      —


      80,995


      (16.5) %


      7.1 %


      0.3 %


      (9.1) %

      Total


      $  321,315


      $    (5,797)


      $  315,518


      $  284,679


      $           —


      $  284,679


      10.8 %


      2.1 %


      0.1 %


      13.0 %



      Three Months Ended December 31,


      Reported Change


      FX Impact


      Constant Currency Change



      2024


      2023


      $


      %


      $


      $


      %

      United States


      $           247,917


      $           203,684


      $             44,233


      21.7 %


      $                    —


      $             44,233


      21.7 %

      International


      67,601


      80,995


      (13,394)


      (16.5) %


      (13)


      (13,407)


      (16.6) %

      Total


      $           315,518


      $           284,679


      $             30,839


      10.8 %


      $                  (13)


      $             30,826


      10.8 %



      Year Ended December 31,


      Reported
      Revenue
      Change
      (%)


      Adjusted
      Revenue
      Impact

      (%)


      Adjusted
      FX

      Impact
      (%)


      Adjusted
      Constant
      Currency
      (%)



      2024


      2023







      Adjusted
      Revenue


      Adjustment


      Revenue


      Adjusted
      revenue


      Adjustment


      Revenue





      United States


      $     902,067


      $           —


      $     902,067


      $     757,151


      $           —


      $     757,151


      19.1 %


      — %


      — %


      19.1 %

      International


      298,345


      (5,797)


      292,548


      301,371


      —


      301,371


      (2.9) %


      1.9 %


      (0.1) %


      (1.1) %

      Total


      $  1,200,412


      $    (5,797)


      $  1,194,615


      $  1,058,522


      $           —


      $  1,058,522


      12.9 %


      0.5 %


      — %


      13.4 %



      Year Ended December 31,


      Reported Change


      FX Impact


      Constant Currency Change



      2024


      2023


      $


      %


      $


      $


      %

      United States


      $           902,067


      $           757,151


      $           144,916


      19.1 %


      $                    —


      $           144,916


      19.1 %

      International


      292,548


      301,371


      (8,823)


      (2.9) %


      (518)


      (9,341)


      (3.1) %

      Total


      $        1,194,615


      $        1,058,522


      $           136,093


      12.9 %


      $                (518)


      $           135,575


      12.8 %

      Penumbra, Inc.

      Reconciliation of Revenue and Adjusted Revenue Change by Product Categories and Geographic Regions to Adjusted Constant
      Currency and Constant Currency Revenue Growth1

      (unaudited)

      (in thousands, except for percentages)




      Three Months Ended December 31,


      Reported
      Revenue
      Change
      (%)


      Adjusted
      Revenue
      Impact

      (%)


      Adjusted
      FX

      Impact
      (%)


      Adjusted
      Constant
      Currency
      (%)



      2024


      2023







      Adjusted
      Revenue


      Adjustment


      Revenue


      Adjusted
      revenue


      Adjustment


      Revenue





      Thrombectomy


      $  222,736


      $    (2,607)


      $  220,129


      $  190,780


      $           —


      $  190,780


      15.4 %


      1.4 %


      0.1 %


      16.9 %

      Embolization
      and Access


      98,579


      (3,190)


      95,389


      93,899


      —


      93,899


      1.6 %


      3.4 %


      0.1 %


      5.1 %

      Total


      $  321,315


      $    (5,797)


      $  315,518


      $  284,679


      $           —


      $  284,679


      10.8 %


      2.1 %


      0.1 %


      13.0 %



      Three Months Ended December 31,


      Reported Change


      FX Impact


      Constant Currency Change



      2024


      2023


      $


      %


      $


      $


      %

      Thrombectomy


      $           220,129


      $           190,780


      $             29,349


      15.4 %


      $                    65


      $             29,414


      15.4 %

      Embolization
      and Access


      95,389


      93,899


      1,490


      1.6 %


      (78)


      1,412


      1.5 %

      Total


      $           315,518


      $           284,679


      $             30,839


      10.8 %


      $                  (13)


      $             30,826


      10.8 %



      Year Ended December 31,


      Reported
      Revenue
      Change
      (%)


      Adjusted
      Revenue
      Impact

      (%)


      Adjusted
      FX

      Impact
      (%)


      Adjusted
      Constant
      Currency
      (%)



      2024


      2023







      Adjusted
      Revenue


      Adjustment


      Revenue


      Adjusted
      revenue


      Adjustment


      Revenue





      Thrombectomy


      $     818,082


      $    (2,607)


      $     815,475


      $     677,343


      $           —


      $     677,343


      20.4 %


      0.4 %


      — %


      20.8 %

      Embolization
      and Access


      382,330


      (3,190)


      379,140


      381,179


      —


      381,179


      (0.5) %


      0.8 %


      (0.1) %


      0.2 %

      Total


      $  1,200,412


      $    (5,797)


      $  1,194,615


      $  1,058,522


      $           —


      $  1,058,522


      12.9 %


      0.5 %


      — %


      13.4 %



      Year Ended December 31,


      Reported Change


      FX Impact


      Constant Currency Change



      2024


      2023


      $


      %


      $


      $


      %

      Thrombectomy


      $           815,475


      $           677,343


      $           138,132


      20.4 %


      $                  (77)


      $           138,055


      20.4 %

      Embolization
      and Access


      379,140


      381,179


      (2,039)


      (0.5) %


      (441)


      (2,480)


      (0.7) %

      Total


      $        1,194,615


      $        1,058,522


      $           136,093


      12.9 %


      $                (518)


      $           135,575


      12.8 %



      Three Months Ended December 31,


      Reported
      Revenue
      Change
      (%)


      Adjusted
      Revenue
      Impact

      (%)


      Adjusted
      FX

      Impact
      (%)


      Adjusted
      Constant
      Currency
      (%)



      2024


      2023







      Adjusted
      Revenue


      Adjustment


      Revenue


      Adjusted
      revenue


      Adjustment


      Revenue





      Thrombectomy





















       United States


      $  180,647


      $           —


      $  180,647


      $  141,891


      $           —


      $  141,891


      27.3 %


      — %


      — %


      27.3 %

       International


      42,089


      (2,607)


      39,482


      48,889


      —


      48,889


      (19.2) %


      5.3 %


      0.4 %


      (13.5) %

       Total Thrombectomy


      222,736


      (2,607)


      220,129


      190,780


      —


      190,780


      15.4 %


      1.4 %


      0.1 %


      16.9 %

      Embolization and Access





















       United States


      67,270


      —


      67,270


      61,793


      —


      61,793


      8.9 %


      — %


      — %


      8.9 %

       International


      31,309


      (3,190)


      28,119


      32,106


      —


      32,106


      (12.4) %


      9.9 %


      0.2 %


      (2.3) %

       Total Embolization
       and Access


      98,579


      (3,190)


      95,389


      93,899


      —


      93,899


      1.6 %


      3.4 %


      0.1 %


      5.1 %

         Total


      $  321,315


      $     (5,797)


      $  315,518


      $  284,679


      $           —


      $  284,679


      10.8 %


      2.1 %


      0.1 %


      13.0 %



      Three Months Ended December  31,


       Change


      FX Impact


      Constant Currency Change



      2024


      2023


      $


      %


      $


      $


      %

      Thrombectomy















       United States


      $          180,647


      $          141,891


      $           38,756


      27.3 %


      $                  —


      $           38,756


      27.3 %

       International


      39,482


      48,889


      (9,407)


      (19.2) %


      65


      (9,342)


      (19.1) %

       Total Thrombectomy


      220,129


      190,780


      29,349


      15.4 %


      65


      29,414


      15.4 %

      Embolization and Access















       United States


      67,270


      61,793


      5,477


      8.9 %


      —


      5,477


      8.9 %

       International


      28,119


      32,106


      (3,987)


      (12.4) %


      (78)


      (4,065)


      (12.7) %

       Total Embolization and
       Access


      95,389


      93,899


      1,490


      1.6 %


      (78)


      1,412


      1.5 %

         Total


      $          315,518


      $          284,679


      $           30,839


      10.8 %


      $                (13)


      $           30,826


      10.8 %



      Year Ended December 31,


      Reported
      Revenue
      Change
      (%)


      Adjusted
      Revenue
      Impact

      (%)


      Adjusted
      FX

      Impact
      (%)


      Adjusted
      Constant
      Currency
      (%)



      2024


      2023







      Adjusted
      Revenue


      Adjustment


      Reported
      Revenue


      Adjusted
      revenue


      Adjustment


      Reported
      Revenue





      Thrombectomy





















       United States


      $     646,711


      $          —


      $     646,711


      $     509,886


      $          —


      $     509,886


      26.8 %


      — %


      — %


      26.8 %

       International


      171,371


      (2,607)


      168,764


      167,457


      —


      167,457


      0.8 %


      1.5 %


      0.1 %


      2.4 %

       Total Thrombectomy


      818,082


      (2,607)


      815,475


      677,343


      —


      677,343


      20.4 %


      0.4 %


      — %


      20.8 %

      Embolization and Access




















       United States


      255,356


      —


      255,356


      247,265


      —


      247,265


      3.3 %


      — %


      — %


      3.3 %

       International


      126,974


      (3,190)


      123,784


      133,914


      —


      133,914


      (7.6) %


      2.4 %


      (0.2) %


      (5.4) %

       Total Embolization
       and Access


      382,330


      (3,190)


      379,140


      381,179


      —


      381,179


      (0.5) %


      0.8 %


      (0.1) %


      0.2 %

         Total


      $  1,200,412


      $    (5,797)


      $  1,194,615


      $  1,058,522


      $          —


      $  1,058,522


      12.9 %


      0.5 %


      — %


      13.4 %



      Year Ended December  31,


       Change


      FX Impact


      Constant Currency Change



      2024


      2023


      $


      %


      $


      $


      %

      Thrombectomy















       United States


      $         646,711


      $         509,886


      $         136,825


      26.8 %


      $                  —


      $         136,825


      26.8 %

       International


      168,764


      167,457


      1,307


      0.8 %


      (77)


      1,230


      0.7 %

       Total Thrombectomy


      815,475


      677,343


      138,132


      20.4 %


      (77)


      138,055


      20.4 %

      Embolization and Access















       United States


      255,356


      247,265


      8,091


      3.3 %


      —


      8,091


      3.3 %

       International


      123,784


      133,914


      (10,130)


      (7.6) %


      (441)


      (10,571)


      (7.9) %

       Total Embolization and
       Access


      379,140


      381,179


      (2,039)


      (0.5) %


      (441)


      (2,480)


      (0.7) %

         Total


      $      1,194,615


      $      1,058,522


      $         136,093


      12.9 %


      $              (518)


      $         135,575


      12.8 %






      1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures.

      Investor Relations
      Penumbra, Inc.
      [email protected] 

      SOURCE Penumbra, Inc.

      Modal title

      Also from this source

      Penumbra, Inc. Reports Third Quarter 2026 Financial Results

      Penumbra, Inc. Reports Third Quarter 2026 Financial Results

      Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2026....

      Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

      Penumbra's CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis (DVT)

      Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) has granted...

      More Releases From This Source

      Explore

      Medical Equipment

      Medical Equipment

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.